company background image
QUIA logo

Quia Pharma OM:QUIA Stock Report

Last Price

SEK 0.036

Market Cap

SEK 53.9m

7D

7.1%

1Y

-15.2%

Updated

20 Nov, 2024

Data

Company Financials

QUIA Stock Overview

Engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. More details

QUIA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Quia Pharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Quia Pharma
Historical stock prices
Current Share PriceSEK 0.036
52 Week HighSEK 0.14
52 Week LowSEK 0.016
Beta0.44
11 Month Change90.53%
3 Month Change-9.27%
1 Year Change-15.22%
33 Year Change-99.95%
5 Year Changen/a
Change since IPO-99.99%

Recent News & Updates

Recent updates

Shareholder Returns

QUIASE BiotechsSE Market
7D7.1%-5.8%-2.1%
1Y-15.2%14.3%10.8%

Return vs Industry: QUIA underperformed the Swedish Biotechs industry which returned 17.8% over the past year.

Return vs Market: QUIA underperformed the Swedish Market which returned 12.5% over the past year.

Price Volatility

Is QUIA's price volatile compared to industry and market?
QUIA volatility
QUIA Average Weekly Movement26.2%
Biotechs Industry Average Movement9.3%
Market Average Movement5.6%
10% most volatile stocks in SE Market11.2%
10% least volatile stocks in SE Market3.3%

Stable Share Price: QUIA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: QUIA's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20043Marcus Bossonwww.quiapeg.com

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.

Quia Pharma AB (publ) Fundamentals Summary

How do Quia Pharma's earnings and revenue compare to its market cap?
QUIA fundamental statistics
Market capSEK 53.94m
Earnings (TTM)-SEK 13.86m
Revenue (TTM)SEK 4.99m

10.8x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QUIA income statement (TTM)
RevenueSEK 4.99m
Cost of RevenueSEK 1.30m
Gross ProfitSEK 3.69m
Other ExpensesSEK 17.55m
Earnings-SEK 13.86m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0093
Gross Margin73.94%
Net Profit Margin-277.59%
Debt/Equity Ratio9.6%

How did QUIA perform over the long term?

See historical performance and comparison